MedTrace Logo

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

NCT06151106 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2025-02-19

No results posted yet for this study

Summary

To determine the efficacy and safety of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.

Conditions

  • Peripheral T Cell Lymphoma
  • Relapsed Peripheral T-Cell Lymphoma
  • Refractory T-Cell Lymphoma

Interventions

DRUG

Chidamide combined with Duvillisib

Specified dose on specified days

Sponsors & Collaborators

  • Fujian Cancer Hospital

    collaborator OTHER_GOV

  • Zhangzhou Affiliated Hospital of Fujian Medical University

    collaborator OTHER

  • Dongguan People's Hospital

    collaborator OTHER_GOV

  • Huizhou Municipal Central Hospital

    collaborator OTHER

  • The First Affiliated Hospital with Nanjing Medical University

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • Shanxi Province Cancer Hospital

    collaborator OTHER

  • The First Affiliated Hospital of Xiamen University

    lead OTHER

Principal Investigators

  • Bing Xu · The First Aiffiliated hosptical of xiamen University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-22
Primary Completion
2026-12-31
Completion
2027-12-25

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06151106 on ClinicalTrials.gov